/
RSS Feed
Germano Di Sciascio, Campus Biomedico University of Rome
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
The anti-inflammatory action of statins may be causing yet another benefit in heart patients: a reduction of atrial fibrillation risk after surgery. The ARMYDA-3 study enrolled patients scheduled for coronary artery bypass grafting, or valve surgery and randomised them to receive 40 mg of atorvastatin or placebo. The results showed a significant reduction of AF in the statin-treated group.
[audio:https://www.audiomedica.com/podcasting/acc2006/germano_di_sciascio.mp3]
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
The anti-inflammatory action of statins may be causing yet another benefit in heart patients: a reduction of atrial fibrillation risk after surgery. The ARMYDA-3 study enrolled patients scheduled for coronary artery bypass grafting, or valve surgery and randomised them to receive 40 mg of atorvastatin or placebo. The results showed a significant reduction of AF in the statin-treated group.
